Nurix Therapeutics, Inc. (NRIX): Capital Expenditures
$14.00M
Year ended 2025-11-30
$10.82M
Trailing 12 months to 2026-05-31
+4.6%
3-year compound annual growth
+25.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-11-30 | $14.00M | +51.0% | 2026-01-28, From 2024-12-01 |
| 2024-11-30 | $9.27M | +10.4% | 2026-01-28, From 2023-12-01 |
| 2023-11-30 | $8.40M | -31.4% | 2026-01-28, From 2022-12-01 |
| 2022-11-30 | $12.24M | +116.3% | 2025-01-28, From 2021-12-01 |
| 2021-11-30 | $5.66M | +24.3% | 2023-02-09, From 2020-12-01 |
| 2020-11-30 | $4.55M | +175.8% | 2022-01-28, From 2019-12-01 |
| 2019-11-30 | $1.65M | n/a | 2022-01-28, From 2018-12-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $14.00M | +51.0% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $339.0K | -39.8% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $8.30M | -0.6% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.0K | -64.5% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $264.0K | -69.6% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $24.81M | +535.1% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $333.0K | n/m |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $220.0K | -29.0% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $42.77M | -45.4% |
Compare NRIX, SPRY, LAB, ARCT side by side · Screen every company in Pharmaceutical Preparations ↗